Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 290

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 1
Chunk 290
---
 — — 19 Share-based compensation—— 2,555 — — 2,555 Net loss—— — (14,619)— (14,619)Balance as of March 31, 202527,535,663$1 $351,519 $(159,633)$123 $192,010 Exercise of stock options29,003— 196 — — 196 Unrealized loss on marketable securities—— — — (85)(85)Vesting of early exercised stock options5,593— 19 — — 19 Share-based compensation—— 2,845 — — 2,845 Issuance of common stock through at-the-market offerings, net of issuance costs920,500— 26,067 — — 26,067 Exercise of stock warrant271— — — — — Issuance of common stock under employee stock purchase plan9,092— 225 — — 225 Net loss—— — (14,912)— (14,912)Balance as of June 30, 202528,500,122$1 $380,871 $(174,545)$38 $206,365 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED AND COMMON STOCK AND STOCKHOLDERS’ EQUITY

(in thousands, except share data)

(unaudited)

Convertible Preferred and Common StockStockholders' Equity (Deficit)Series A Convertible PreferredStockSeries A-1 ConvertiblePreferred StockSeries B Convertible PreferredStockClass B Convertible CommonStockCommon StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome (Loss)Stockholders' Equity(Deficit)SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance as of December 31, 2023(1)21,977,282$44,621 2,950,548$9,893 28,019,181$82,976 2,744,184$5,900 1,969,360$10 $2,517 $(95,245)$6 $(92,712)Conversion of convertible preferred stock and Class B convertible common stock to common stock as a result of the